Equivalence of plasma and serum for clinical measurement of p-tau217: comparative analyses of four blood-based assays.

ABSTRACT:

Background

Phosphorylated tau (p-tau) 217 is a promising blood biomarker for Alzheimer's disease (AD). However, most p-tau217 assays have been validated solely in ethylenediaminetetraacetic acid (EDTA) plasma, leaving the clinical applicability of serum p-tau217 largely unexplored despite serum being a preferred matrix in many clinical laboratories. To address this gap, we compared p-tau217 concentrations and diagnostic performances in matched plasma and serum samples using four research-use-only assays, including three from commercial sources i.e., Lumipulse, ALZpath, NULISA, and one from University of Pittsburgh.

Methods

Paired plasma and serum samples were processed from the same venipuncture collection and assessed with the four p-tau217 assays following manufacturer-rec

SUBMITTER: Chen Y 

PROVIDER: S-EPMC11703320 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature